ATE524972T1 - Poly-tlr-antagonist - Google Patents

Poly-tlr-antagonist

Info

Publication number
ATE524972T1
ATE524972T1 AT07825710T AT07825710T ATE524972T1 AT E524972 T1 ATE524972 T1 AT E524972T1 AT 07825710 T AT07825710 T AT 07825710T AT 07825710 T AT07825710 T AT 07825710T AT E524972 T1 ATE524972 T1 AT E524972T1
Authority
AT
Austria
Prior art keywords
poly
tlr antagonist
tlr
antagonist
Prior art date
Application number
AT07825710T
Other languages
English (en)
Inventor
Indravadan Modi
Bakulesh Mafatial Khamar
Original Assignee
Cadila Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Pharmaceuticals Ltd filed Critical Cadila Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE524972T1 publication Critical patent/ATE524972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
AT07825710T 2006-11-23 2007-11-21 Poly-tlr-antagonist ATE524972T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1931MU2006 2006-11-23
PCT/IB2007/003581 WO2008062288A2 (en) 2006-11-23 2007-11-21 Poly-tlr antagonist

Publications (1)

Publication Number Publication Date
ATE524972T1 true ATE524972T1 (de) 2011-10-15

Family

ID=39430114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07825710T ATE524972T1 (de) 2006-11-23 2007-11-21 Poly-tlr-antagonist

Country Status (13)

Country Link
US (1) US8333978B2 (de)
EP (2) EP2096914B1 (de)
JP (1) JP5358450B2 (de)
AP (1) AP2752A (de)
AT (1) ATE524972T1 (de)
AU (1) AU2007323134B2 (de)
CA (1) CA2670124C (de)
EA (1) EA023046B1 (de)
ES (1) ES2370535T3 (de)
GB (2) GB2450580B (de)
PL (1) PL2096914T3 (de)
WO (1) WO2008062288A2 (de)
ZA (1) ZA200903523B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2131858A4 (de) * 2007-03-20 2011-11-23 Cadila Pharmaceuticals Ltd P38-hemmer
WO2009089399A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
WO2012011100A1 (en) 2010-07-19 2012-01-26 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases
GB201013785D0 (en) * 2010-08-17 2010-09-29 Ucl Business Plc Treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE127345T1 (de) * 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
EP0365087B1 (de) * 1988-10-21 1992-07-22 Akzo N.V. Immunotoxine zur Behandlung bzw. Prophylaxe von Autoimmunkrankheiten
US5681824A (en) 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
AUPO359396A0 (en) * 1996-11-13 1996-12-05 Amrad Operations Pty. Limited A method of treatment and pharmaceutical compositions useful for same
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
WO2002056898A2 (en) * 2001-01-17 2002-07-25 Mafatlal Khamar Bakulesh Immunomodulator for the management of human immunodeficiency virus (hiv) disease/infection
GB0106987D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeuitic agent
GB0106985D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeutic agent
JP2005532981A (ja) * 2001-09-25 2005-11-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 免疫媒介疾患における病原性免疫応答を調節するためのエピトープ特異的およびサイトカイン／抗サイトカイン併用免疫治療法
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
GB2392839A (en) * 2002-03-08 2004-03-17 Bakulesh Mafatlal Khamar Use of Mycobacterium w in the treatment of tuberculosis
PT1490103E (pt) * 2002-03-13 2008-08-05 Cadila Pharmaceuticals Ltd Processo para a preparação de composição farmacêutica que compreende mycobacterium w no tratamento de asma (doença pulmonar obstrutiva)
WO2003075827A2 (en) * 2002-03-13 2003-09-18 Modi, Rajiv, Indravadan Use of mycobacterium w in the treatment of asthama(obstructive lung disease)
WO2004071465A2 (en) 2003-02-12 2004-08-26 Eisai Co., Ltd Methods and kits for use in the diagnosis and treatment of endotoxemia
EP2131858A4 (de) * 2007-03-20 2011-11-23 Cadila Pharmaceuticals Ltd P38-hemmer

Also Published As

Publication number Publication date
WO2008062288A8 (en) 2008-10-09
WO2008062288A3 (en) 2009-04-23
GB2450580B (en) 2010-04-14
EP2359837A1 (de) 2011-08-24
GB2450580A (en) 2008-12-31
GB0807084D0 (en) 2008-05-21
GB201000798D0 (en) 2010-03-03
EP2096914A2 (de) 2009-09-09
AP2009004881A0 (en) 2009-06-30
EP2096914A4 (de) 2010-05-12
ZA200903523B (en) 2010-05-26
PL2096914T3 (pl) 2012-02-29
ES2370535T3 (es) 2011-12-19
EA200970503A1 (ru) 2009-12-30
AU2007323134A1 (en) 2008-05-29
GB2464231B (en) 2010-08-04
AU2007323134B2 (en) 2013-05-02
US8333978B2 (en) 2012-12-18
WO2008062288A2 (en) 2008-05-29
GB2464231A (en) 2010-04-14
JP2010510303A (ja) 2010-04-02
CA2670124C (en) 2015-04-21
JP5358450B2 (ja) 2013-12-04
CA2670124A1 (en) 2008-05-29
EP2096914B1 (de) 2011-09-21
EA023046B1 (ru) 2016-04-29
US20100062026A1 (en) 2010-03-11
AP2752A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
HRP20151108T1 (xx) Antagonisti nogo-receptora
DE602006019782D1 (de) Kapselperforationsmodul
DE602007002544D1 (de) Nuancierungsmittel
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007009267D1 (de) Reifenaufblasverfahren
DE602007003893D1 (de) Kippambossanordnung
DE602007009650D1 (de) Spiroindolinonderivate
AT504580A3 (de) Scan-einrichtung
DE602007006947D1 (de) Pyridopyrimidinonderivate
DE602007000258D1 (de) Kassetteneinspannmechanismus
DE602007009337D1 (de) Tastfeedbackvorrichtung
DE602007001280D1 (de) Getränkeextraktor
DE602007008400D1 (de) Kaliummonopersulfatlösungen
DE602007010359D1 (de) Azaspiroderivate
DE602006020192D1 (de) Riemenscheibenanorndung
DE502007001629D1 (de) Rfahren
BRPI0810926A2 (pt) Antagonista de crig
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007001098D1 (de) Spindelmäheinheit
DE602007000501D1 (de) Breitbandrichtkoppler
DE602007004080D1 (de) Tintenstrahlaufnehmer
DE602007007460D1 (de) Sehkrafttestsystem
DE502007000361D1 (de) Stanznieteinheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties